As part of our ongoing commitment to reliability, accessibility, and quality in the healthcare supply chain, SCA Pharma is pleased to announce an expanded distribution approach for our core pharmaceutical products. Healthcare professionals can now access SCA Pharma’s trusted offerings through a broader network of purchasing platforms, including Medigi as an alternate location. This important…
Product development in 503B outsourcing facilities involves a detailed, highly regulated process. Every compounded medication produced by facilities like SCA Pharma must be safe, compliant, and aligned with the needs of healthcare institutions. This blog dives deeper into the product development process, covering each phase from discovery to post-launch monitoring. The Product Development Process The development…
In the fast-paced healthcare environment, access to critical medications is essential for providing timely, effective patient care. Ensuring the right medications are on hand when needed can be a logistical challenge for hospital pharmacies. This is where a reliable 503B outsourcing facility offering a “Buy & Ship Now” option becomes invaluable. By allowing hospital pharmacies…
On January 27, 2022, the FDA announced its decision to not include Glycopyrrolate on the 503B bulks list. Following this announcement, outsourcing facilities will not be permitted to compound the drug-using bulk API, unless the product appears in the future on the FDA’s drug shortage list. Glycopyrrolate is not currently on the drug shortage list.…
SCA Pharma will exhibit at the Health Connect Partners Hospital Pharmacy online summer session and reverse expo June 14-July 1. The conference, which brings together hospital pharmacy decision-makers with suppliers, will allow hospitals to see SCA Pharma’s diverse product portfolio of sterile compounded pharmaceuticals. Visitors to SCA Pharma’s virtual booth can learn more about our quality initiatives and the benefits of outsourcing our…
In our ongoing effort to enhance our customers’ experience, SCA Pharma has responded to feedback and made several changes to the customer portal. Here are recent updates: Watch for a “chat” feature coming soon. To see these recent changes, log in to the customer portal here or contact a salesperson for help placing an order…
SCA Pharma’s customers have requested extended Beyond Use Dating (BUD), and we are pleased to help meet their needs by extending BUDs on 69 products to date, while still maintaining our stringent quality controls. We anticipate extending BUDs on most or all of our products. Beyond Use Dating (BUD) on compounded sterile preparations is important…
SCA Pharma has made it easy for customers to get products quickly on non-recurring orders, and this tutorial walks customers through the process. “Buy and Ship Now” offers an inventory of finished goods that can be available to ship within one business day, when ordered by 3 p.m. EST. The products listed in the portal…
SCA Pharma, an FDA-registered outsourcing facility, today announced that it will expand its operations in Little Rock. SCA will be investing more than $10 million and will create the opportunity to double its current Little Rock workforce of 180 people. Additionally, the investment will allow SCA Pharma to renovate an existing 42,000-square-foot facility at the…
SCA Pharma, an FDA-registered outsourcing facility, plans to expand its sterile pharmaceutical manufacturing facility in Windsor, CT, by 40 percent. SCA Pharma has experienced continued growth during the past five years and has emerged as a leading manufacturer of compounded pharmaceuticals. The company continually seeks new opportunities to meet customer and patient needs, and creating…